Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality. The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses: 1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.

Who May Be Eligible (Plain English)

Who May Qualify: - 18 years old - Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus. Who Should NOT Join This Trial: - Refusal to give willing to sign a consent form - Treatment with PCSK9 inhibitors - Any acute or chronic condition that would limit the ability of the patient to participate in the study - Control group: proteinuria Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * 18 years old * Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus. Exclusion Criteria: * Refusal to give informed consent * Treatment with PCSK9 inhibitors * Any acute or chronic condition that would limit the ability of the patient to participate in the study * Control group: proteinuria

Locations (1)

Kolding Sygehus, Lillebælt Hospital
Kolding, Denmark